全文获取类型
收费全文 | 998419篇 |
免费 | 76371篇 |
国内免费 | 2620篇 |
专业分类
耳鼻咽喉 | 12993篇 |
儿科学 | 34519篇 |
妇产科学 | 28528篇 |
基础医学 | 145534篇 |
口腔科学 | 27748篇 |
临床医学 | 90412篇 |
内科学 | 194047篇 |
皮肤病学 | 22960篇 |
神经病学 | 79278篇 |
特种医学 | 38510篇 |
外国民族医学 | 305篇 |
外科学 | 149758篇 |
综合类 | 23746篇 |
一般理论 | 386篇 |
预防医学 | 78003篇 |
眼科学 | 22620篇 |
药学 | 71986篇 |
3篇 | |
中国医学 | 2032篇 |
肿瘤学 | 54042篇 |
出版年
2018年 | 10626篇 |
2017年 | 8279篇 |
2016年 | 9410篇 |
2015年 | 10672篇 |
2014年 | 14477篇 |
2013年 | 22093篇 |
2012年 | 29101篇 |
2011年 | 30951篇 |
2010年 | 18561篇 |
2009年 | 17500篇 |
2008年 | 28891篇 |
2007年 | 30579篇 |
2006年 | 31104篇 |
2005年 | 29764篇 |
2004年 | 29034篇 |
2003年 | 27869篇 |
2002年 | 26874篇 |
2001年 | 46982篇 |
2000年 | 48108篇 |
1999年 | 40316篇 |
1998年 | 11197篇 |
1997年 | 10111篇 |
1996年 | 10179篇 |
1995年 | 9786篇 |
1994年 | 9103篇 |
1993年 | 8489篇 |
1992年 | 32267篇 |
1991年 | 31477篇 |
1990年 | 31026篇 |
1989年 | 29891篇 |
1988年 | 27179篇 |
1987年 | 27332篇 |
1986年 | 25447篇 |
1985年 | 24612篇 |
1984年 | 18407篇 |
1983年 | 15527篇 |
1982年 | 9292篇 |
1981年 | 8381篇 |
1979年 | 16872篇 |
1978年 | 12222篇 |
1977年 | 10321篇 |
1976年 | 9758篇 |
1975年 | 10182篇 |
1974年 | 12323篇 |
1973年 | 11849篇 |
1972年 | 10886篇 |
1971年 | 10115篇 |
1970年 | 9383篇 |
1969年 | 8730篇 |
1968年 | 8106篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
141.
J.J. Crowley R.B. Warren J.C. Cather 《Journal of the European Academy of Dermatology and Venereology》2019,33(9):1676-1684
Psoriasis is a chronic disease that requires long‐term treatment. Consequently, understanding the safety and tolerability of any potential treatment over time is critical to effective prescribing. The biologic agents currently available for the treatment of psoriasis target a number of different inflammatory cytokines involved in psoriasis disease pathogenesis. The monoclonal antibodies tildrakizumab, guselkumab and risankizumab target the p19 subunit that is specific to interleukin (IL)‐23. This article reviews published data on the safety of these IL‐23p19 inhibitors in patients with psoriasis compared with other currently available biologic therapies. Data from randomized, placebo‐ and active‐controlled phase 3 clinical trials show tildrakizumab, guselkumab and risankizumab to have a favourable risk–benefit profile in patients with moderate to severe psoriasis. No significant safety concerns have been observed for any of these IL‐23p19 inhibitors in the data published to date. The most commonly reported adverse events (AEs) associated with these agents in phase 3 studies were upper respiratory tract infections. No increase was seen in rates of serious infections, malignancies or major adverse cardiovascular events, with no signals suggestive of an elevated risk of opportunistic infections, active tuberculosis or reactivation of latent tuberculosis infection, mucocutaneous Candida infections, triggering or worsening of inflammatory bowel disease, demyelinating disorders or suicidal ideation. Selectively targeting IL‐23p19 may help avoid AEs that have been associated with biologic agents with other mechanisms of action. Data from long‐term extension studies and patient registries will further establish the safety profile of IL‐23p19 inhibitors for the treatment of moderate to severe psoriasis in routine practice. 相似文献
142.
143.
Umar Nadia K. Badshah Maaz B. Sandrasegaran Kumar Ghabril Marwan Agarwal Saurabh Tann Mark Lacerda Marco Kwo Paul Y. 《Digestive diseases and sciences》2015,60(7):2196-2200
Digestive Diseases and Sciences - To determine whether the presence of portal vein thrombosis (PVT) where venous flow within the liver may be altered may delay the diagnosis of HCC and be... 相似文献
144.
Letter: faecal volatile organic metabolites,promising biomarkers in inflammatory bowel disease and Letter: faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease. Authors’ reply
下载免费PDF全文
![点击此处可从《Alimentary pharmacology & therapeutics》网站下载免费的PDF全文](/ch/ext_images/free.gif)
I. Ahmed R. Greenwood B. Costello N. Ratcliffe C. Probert 《Alimentary pharmacology & therapeutics》2016,43(11):1241-1242
145.
146.
147.
Jennifer L. Brown Lisa B. Haddad Nicole K. Gause Sarah Cordes Cecilia Bess Caroline C. King 《Women & health》2019,59(3):305-317
This study qualitatively examined factors that influenced contraceptive choices in a sample of young, HIV-infected women. Individual qualitative interviews were conducted among 30 vertically and horizontally HIV-infected women (n = 26 African American) from the ages of 14 to 24 years (Mean age = 20.9 years). We recruited sample groups with the following characteristics: (a) current contraceptive/condom use with ≥1 child (n = 11); (b) current contraceptive/condom use with no children (n = 12); and (c) no current contraceptive/condom use with no children (n = 7). A semi-structured interview guide was used to ask participants about factors influencing past and current contraceptive choices. Individual interviews were digitally recorded and transcribed verbatim; analyses to identify core themes were informed by the Grounded Theoretical approach. Young, HIV-infected women did not identify their HIV serostatus or disease-related concerns as influential in their contraceptive decisions. However, they reported that recommendations from health-care providers and input from family and friends influenced their contraceptive choices. They also considered a particular method’s advantages (e.g., menstrual cycle improvements) and disadvantages (e.g., increased pill burden) when selecting a method. Findings suggested that HIV-infected young women’s contraceptive decisions were influenced by factors other than those related to their infection. 相似文献
148.
J. Rodríguez-Carrio A. Martínez-Zapico I. Cabezas-Rodríguez L. Benavente Á.I. Pérez-Álvarez P. López J.B. Cannata-Andía M. Naves-Díaz A. Suárez 《Nutrition, metabolism, and cardiovascular diseases : NMCD》2019,29(2):135-143
Background and aims
Since accelerated atherosclerosis has been reported in systemic lupus erythematosus (SLE), predictive biomarkers of cardiovascular disease (CVD) are needed. Among non-traditional risk factors, bone mineral density (BMD) has been related to CVD. However, its role in SLE remains controversial. This study aims to analyze the associations of subclinical atherosclerosis with traditional and non-traditional CV risk factors.Methods and results
In a cross-sectional study, atherosclerosis burden was compared between 112 female SLE patients and 31 controls. Plaque number and carotid intima-media wall thickness (cIMT) were assessed by ultrasonography. In a retrospective study, BMD determinations obtained 5-years before the ultrasonography assessment were analyzed in a subgroup of 62 patients. Plaque frequency was increased in SLE, even in patients without CV events or carotid wall thickening. cIMT was increased in patients with CVD, positively correlated with body mass index (BMI). Interestingly, a paradoxical effect of BMI on carotid parameters was observed. Whereas underweight patients (BMI < 20) showed increased prevalence of carotid plaques with low cIMT, those with BMI > 30 showed higher cIMT and plaque burden. Overweight patients (25 < BMI<30) exhibited both elevated cIMT and plaque number. BMI was an independent predictor of BMD. In our retrospective study, patients with either clinical or subclinical CVD exhibited lower BMD levels than their CV-free counterparts. A low lumbar spine BMD independently predicted CVD development after adjusting for confounders.Conclusion
SLE was associated with a higher subclinical atherosclerosis burden, a bimodal effect being observed for BMI. Decreased BMD can be a CV risk biomarker in SLE. 相似文献149.
Renaud Snanoudj Nassim Kamar Elisabeth Cassuto Sophie Caillard Marie Metzger Pierre Merville Antoine Thierry Isabelle Jollet Philippe Grimbert Dany Anglicheau Marc Hazzan Gabriel Choukroun Bruno Hurault De Ligny Bénedicte Janbon Vincent Vuiblet Anne Devys Yann Le Meur Michel Delahousse Jean-Luc Taupin 《Kidney international》2019,95(6):1471-1485
150.